Digestive Diseases and Sciences

, Volume 52, Issue 1, pp 84–92 | Cite as

Effect of Rebamipide on the Colonic Barrier in Interleukin-10-Deficient Mice

  • David Laharie
  • Sandrine Ménard
  • Corinne Asencio
  • Teresita Vidal-Martinez
  • Anne Rullier
  • Frank Zerbib
  • Céline Candalh
  • Francis Mégraud
  • Martine Heyman
  • Tamara Matysiak-Budnik
Original Paper


Our aim was to study the effect of a mucosal protective agent, rebamipide, on the colonic barrier and the immune response in colitis-prone interleukin-10-deficient (IL-10−/−) C57BL/6 mice infected with Helicobacter hepaticus. After sacrifice, in all mice, control, or previously infected with H. hepaticus, or previously infected and treated with rebamipide enema, a histological examination of colonic samples was performed, intestinal permeability was studied in Ussing chamber, and mesenteric lymph node proliferation and cytokine secretion were measured. Mice treated with rebamipide presented a reinforcement of the distal colonic epithelial barrier, an increase of mesenteric lymph node cells proliferation, and of IFNγ and IL-12 secretion. These results indicate that in IL-10−/− mice with mild colitis, rectally administered rebamipide reinforces the distal colonic barrier and has a slight Th1 immuno-stimulatory effect on mesenteric lymph node cells. These properties could be helpful in the management of some inflammatory bowel diseases.


Rebamipide Intestinal permeability Colitis Interleukin 10 Immune response 



This work was supported by Otsuka Pharmaceutical, Tokyo, Japan.


  1. 1.
    Meddings JB (1997) Review article: intestinal permeability in Crohn's disease. Aliment Pharmacol Ther 11(Suppl 3):47–53PubMedGoogle Scholar
  2. 2.
    Schmitz H, Barmeyer C, Fromm M, Runkel N, Foss HD, Bentzel CJ, Riecken EO, Schulzke JD (1999) Altered tight junction structure contributes to the impaired epithelial barrier function in ulcerative colitis. Gastroenterology 116:301–309PubMedCrossRefGoogle Scholar
  3. 3.
    Soderholm JD, Olaison G, Peterson KH, Franzen LE, Lindmark T, Wiren M, Tagesson C, Sjodahl R (2002) Augmented increase in tight junction permeability by luminal stimuli in the non-inflamed ileum of Crohn's disease. Gut 50:307–313PubMedCrossRefGoogle Scholar
  4. 4.
    Zareie M, Singh PK, Irvine EJ, Sherman PM, McKay DM, Perdue MH (2001) Monocyte/macrophage activation by normal bacteria and bacterial products: implications for altered epithelial function in Crohn's disease. Am J Pathol 158:1101–1109PubMedGoogle Scholar
  5. 5.
    Irvine EJ, Marshall JK (2000) Increased intestinal permeability precedes the onset of Crohn's disease in a subject with familial risk. Gastroenterology 119:1740–1744PubMedCrossRefGoogle Scholar
  6. 6.
    Arakawa T, Kobayashi K, Yoshikawa T, Tarnawski A (1998) Rebamipide: overview of its mechanisms of action and efficacy in mucosal protection and ulcer healing. Dig Dis Sci 43:5S–13SPubMedGoogle Scholar
  7. 7.
    Matysiak-Budnik T, de Mascarel A, Abely M, Mayo K, Heyman M, Megraud F (2000) Positive effect of rebamipide on gastric permeability in mice after eradication of Helicobacter felis. Scand J Gastroenterol 35:470–475PubMedCrossRefGoogle Scholar
  8. 8.
    Matysiak-Budnik T, Thomas-Collignon A, Megraud F, Heyman M (2001) Alterations of epithelial permeability by Helicobacter and IL-1beta in vitro: protective effect of rebamipide. Dig Dis Sci 46:1558–1566PubMedCrossRefGoogle Scholar
  9. 9.
    Kishimoto S, Haruma K, Tari A, Sakurai K, Nakano M, Nakagawa Y (2000) Rebamipide, an antiulcer drug, prevents DSS-induced colitis formation in rats. Dig Dis Sci 45:1608–1616PubMedCrossRefGoogle Scholar
  10. 10.
    Makiyama K, Takeshima F, Kawasaki H, Zea-Iriarte WL (2000) Anti-inflammatory effect of rebamipide enema on proctitis type ulcerative colitis: a novel therapeutic alternative. Am J Gastroenterol 95:1838–1839PubMedCrossRefGoogle Scholar
  11. 11.
    Li X, Fox JG, Whary MT, Yan L, Shames B, Zhao Z (1998) SCID/NCr mice naturally infected with Helicobacter hepaticus develop progressive hepatitis, proliferative typhlitis, and colitis. Infect Immun 66:5477–5484PubMedGoogle Scholar
  12. 12.
    Shomer NH, Dangler CA, Schrenzel MD, Fox JG (1997) Helicobacter bilis-induced inflammatory bowel disease in SCID mice with defined flora. Infect Immun 65:4858–4864PubMedGoogle Scholar
  13. 13.
    Kullberg MC, Ward JM, Gorelick PL, Caspar P, Hieny S, Cheever A, Jankovic D, Sher A (1998) Helicobacter hepaticus triggers colitis in specific-pathogen-free interleukin-10 (IL-10)-deficient mice through an IL-12- and gamma interferon-dependent mechanism. Infect Immun 66:5157–5166PubMedGoogle Scholar
  14. 14.
    Fox JG, Dewhirst FE, Shen Z, Feng Y, Taylor NS, Paster BJ, Ericson RL, Lau CN, Correa P, Araya JC, Roa I (1998) Hepatic Helicobacter species identified in bile and gallbladder tissue from Chileans with chronic cholecystitis. Gastroenterology 114:755–763PubMedCrossRefGoogle Scholar
  15. 15.
    McCarthy J, O'Mahony L, O'Callaghan L, Sheil B, Vaughan EE, Fitzsimons N, Fitzgibbon J, O'Sullivan GC, Kiely B, Collins JK, Shanahan F (2003) Double-blind, placebo-controlled trial of two probiotic strains in interleukin-10 knockout mice and mechanistic link with cytokine balance. Gut 52:975–980PubMedCrossRefGoogle Scholar
  16. 16.
    Maehly AC, Chance B (1954) The assay of catalases and peroxidases. In: Glick D (ed) Methods of biochemical analysis, vol 1. Wiley Interscience, New York, pp 357–398CrossRefGoogle Scholar
  17. 17.
    Matysiak-Budnik T, van Niel G, Megraud F, Mayo K, Bevilacqua C, Gaboriau-Routhiau V, Moreau MC, Heyman M (2003) Gastric Helicobacter infection inhibits development of oral tolerance to food antigens in mice. Infect Immun 71:5219–5224PubMedCrossRefGoogle Scholar
  18. 18.
    Naito Y, Yoshikawa T, Tanigawa T, Sakurai K, Yamasaki K, Uchida M, Kondo M (1995) Hydroxyl radical scavenging by rebamipide and related compounds: electron paramagnetic resonance study. Free Rad Biol Med 18:117–123PubMedCrossRefGoogle Scholar
  19. 19.
    Yamasaki K, Kanbe T, Chijiwa T, Ishiyama H, Morita S (1987) Gastric mucosal protection by OPC-12759, a novel antiulcer compound in rat. Eur J Pharmacol 142:29CrossRefGoogle Scholar
  20. 20.
    Soderholm JD, Peterson KH, Olaison G, Franzen LE, Westrom B, Magnusson KE, Sjodahl R (1999) Epithelial permeability to proteins in the noninflamed ileum of Crohn's disease? Gastroenterology 117:65–72PubMedCrossRefGoogle Scholar
  21. 21.
    Soderholm JD, Streutker C, Yang PC, Paterson C, Singh PK, McKay DM, Sherman PM, Croitoru K, Perdue MH (2004) Increased epithelial uptake of protein antigens in the ileum of Crohn's disease mediated by tumour necrosis factor alpha. Gut 53:1817–1824PubMedCrossRefGoogle Scholar
  22. 22.
    Suenaert P, Bulteel V, Lemmens L, Noman M, Geypens B, Van Assche G, Geboes K, Ceuppens JL, Rutgeerts P (2002) Anti-tumor necrosis factor treatment restores the gut barrier in Crohn's disease. Am J Gastroenterol 97:2000–2004PubMedCrossRefGoogle Scholar
  23. 23.
    Aihara M, Imagawa K, Funakoshi Y, Ohmoto Y, Kikuchi M (1998) Effects of rebamipide on production of several cytokines by human peripheral blood mononuclear cells. Dig Dis Sci 43:160S–166SPubMedGoogle Scholar
  24. 24.
    Aihara M, Azuma A, Takizawa H, Tsuchimoto D, Funakoshi Y, Shindo Y, Ohmoto Y, Imagawa K, Kikuchi M, Mukaida N, Matsushima K (1998) Molecular analysis of suppression of interleukin-8 production by rebamipide in Helicobacter pylori-stimulated gastric cancer cell lines. Dig Dis Sci 43:174S–180SPubMedGoogle Scholar
  25. 25.
    Danielsson D, Jurstrand M (1998) Nonopsonic activation of neutrophils by Helicobacter pylori is inhibited by rebamipide. Dig Dis Sci 43:167S–173SPubMedGoogle Scholar
  26. 26.
    Nagano C, Wakebe H, Azuma A, Imagawa K, Kikuchi M (1998) IFN-gamma-induced iNOS mRNA expression is inhibited by rebamipide in murine macrophage RAW264.7 cells. Dig Dis Sci 43:118S–124SPubMedGoogle Scholar
  27. 27.
    Bamba H, Ota S, Kato A, Miyatani H, Kawamoto C, Yoshida Y, Fujiwara K (2003) Effect of rebamipide on prostaglandin receptors-mediated increase of inflammatory cytokine production by macrophages. Aliment Pharmacol Ther 18(Suppl 1):113–118PubMedCrossRefGoogle Scholar
  28. 28.
    Iwai A, Iwashita E (1998) Changes in colonic inflammation induced by dextran sulfate sodium (DSS) during short- and long-term administration of rebamipide. Dig Dis Sci 43:143S–147SPubMedGoogle Scholar
  29. 29.
    Sakurai K, Osaka T, Yamasaki K (1998) Protection by rebamipide against acetic acid-induced colitis in rats: relationship with its antioxidative activity. Dig Dis Sci 43:125S–133SPubMedGoogle Scholar
  30. 30.
    Hahm KB, Kim DH, Lee KM, Lee JS, Surh YJ, Kim YB, Yoo BM, Kim JH, Joo HJ, Cho YK, Nam KT, Cho SW (2003) Effect of long-term administration of rebamipide on Helicobacter pylori infection in mice. Aliment Pharmacol Ther 18(Suppl 1):24–38PubMedCrossRefGoogle Scholar
  31. 31.
    Isolauri E, Joensuu J, Suomalainen H, Luomala M, Vesikari T (1995) Improved immunogenicity of oral D x RRV reassortant rotavirus vaccine by Lactobacillus casei GG. Vaccine 13:310–312PubMedCrossRefGoogle Scholar
  32. 32.
    Menard S, Candalh C, Bambou JC, Terpend K, Cerf-Bensussan N, Heyman M (2004) Lactic acid bacteria secrete metabolites retaining anti-inflammatory properties after intestinal transport. Gut 53:821–828PubMedCrossRefGoogle Scholar
  33. 33.
    Benyacoub J, Czarnecki-Maulden GL, Cavadini C, Sauthier T, Anderson RE, Schiffrin EJ, von der WT (2003) Supplementation of food with Enterococcus faecium (SF68) stimulates immune functions in young dogs. J Nutr 133:1158–1162PubMedGoogle Scholar
  34. 34.
    Benyacoub J, Perez PF, Rochat F, Saudan KY, Reuteler G, Antille N, Humen M, De Antoni GL, Cavadini C, Blum S, Schiffrin EJ (2005) Enterococcus faecium SF68 enhances the immune response to Giardia intestinalis in mice. J Nutr 135:1171–1176PubMedGoogle Scholar
  35. 35.
    Pelto L, Salminen SJ, Isolauri E (1998) Lactobacillus GG modulates milk-induced immune inflammatory response in milk-hypersensitive adults. Nutrition Today 31(Suppl):45S–46SGoogle Scholar
  36. 36.
    Menard S, Candalh C, Bambou JC, Terpend K, Cerf-Bensussan N, Heyman M (2004) Lactic acid bacteria secrete metabolites retaining anti-inflammatory properties after intestinal transport. Gut 53:821–828PubMedCrossRefGoogle Scholar
  37. 37.
    Madara JL, Stafford J (1989) Interferon-gamma directly affects barrier function of cultured intestinal epithelial monolayers. J Clin Invest 83:724–727PubMedGoogle Scholar
  38. 38.
    Podolsky DK (2002) Inflammatory bowel disease. N Engl J Med 347:417–429PubMedCrossRefGoogle Scholar
  39. 39.
    Fuss IJ, Heller F, Boirivant M, Leon F, Yoshida M, Fichtner-Feigl S, Yang Z, Exley M, Kitani A, Blumberg RS, Mannon P, Strober W (2004) Nonclassical CD1d-restricted NK T cells that produce IL-13 characterize an atypical Th2 response in ulcerative colitis. J Clin Invest 113:1490–1497PubMedCrossRefGoogle Scholar
  40. 40.
    Berg DJ, Davidson N, Kuhn R, Muller W, Menon S, Holland G, Thompson-Snipes L, Leach MW, Rennick D (1996) Enterocolitis and colon cancer in interleukin-10-deficient mice are associated with aberrant cytokine production and CD4(+) TH1-like responses. J Clin Invest 98:1010–1020PubMedCrossRefGoogle Scholar
  41. 41.
    Dieleman LA, Arends A, Tonkonogy SL, Goerres MS, Craft DW, Grenther W, Sellon RK, Balish E, Sartor RB (2000) Helicobacter hepaticus does not induce or potentiate colitis in interleukin-10-deficient mice. Infect Immun 68:5107–5113PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, Inc. 2006

Authors and Affiliations

  • David Laharie
    • 1
  • Sandrine Ménard
    • 2
  • Corinne Asencio
    • 1
  • Teresita Vidal-Martinez
    • 2
  • Anne Rullier
    • 3
  • Frank Zerbib
    • 1
  • Céline Candalh
    • 2
  • Francis Mégraud
    • 1
  • Martine Heyman
    • 2
  • Tamara Matysiak-Budnik
    • 2
    • 4
  1. 1.INSERM-ERI 10Université Victor SegalenBordeauxFrance
  2. 2.INSERM U793Faculté Necker-René DescartesBordeauxFrance
  3. 3.Service d’Anatomo-pathologieHôpital PellegrinBordeauxFrance
  4. 4.INSERM U793Faculté Necker-René DescartesParisFrance

Personalised recommendations